Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000330

Drug Information
NameGenistein
SynonymsKBio2_007700; KBio2_005132; LMPK12050218; NCGC00025005-04; HSDB 7475; NCGC00025005-05; NCGC00025005-01; NSC36586; NCGC00025005-06; 4',5, 7-Trihydroxyisoflavone; Genestein; Spectrum4_001543; UPCMLD-DP096:001; 4′,5,7-Trihydroxyisoflavone; Bio1_000445; IN1327; ISOFLAVONE, 4',5,7-TRIHYDROXY-; CHEMBL44; C06563; SIPI-9764-I; 446-72-0; G6649_SIGMA; 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; BB_NC-1017; GEN; SMP1_000133; KBioGR_002564; DB01645; 5-18-04-00594 (Beilstein Handbook Reference); NCGC00025005-07; CCRIS 7675; cMAP_000086; CID5280961; 4,6,7-Trihydroxyisoflavone; STO514; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; S1342_Selleck; Lactoferrin-genistein; Lopac-G-6649; AKOS001590147; NCI60_003369; genistein; SIPI 807-1; NCGC00015479-01; CHEBI:28088; G6776_SIGMA; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; NSC 36586; G10000; SMR000112580; Oprea1_224620; Bio1_001423; UPCMLD-DP096; Spectrum3_000678; C.I. 75610; D019833; 5,7,4'-Trihydroxyisoflavone; GENISTEIN (ENDOCRINE DISRUPTER); KBio3_001595; KBioSS_000800; Differenol A; STK801619; KBio2_000800; EINECS 207-174-9; NPI 031L; MolPort-000-003-911; BRN 0263823; Tocris-1110; Spectrum_000320; nchembio.76-comp6; KBio2_005936; Bio1_000934; 4',5,7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; KBioGR_002006; NCGC00169711-01; I06-0431; PTI G4660 (Genistein); KBio1_001345; G0272; Genisterin; AC1NQXT4; BIDD:ER0113; BSPBio_002375; PTI-G4660; Genisteol; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 4',5,7-Trihydroxy isoflavone; Prunetol; BRD-K43797669-001-02-3; BRD-K43797669-001-03-1; EU-0100520; Spectrum5_000106; Oprea1_437815; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); NCGC00015479-13; SpecPlus_000305; 1x7r; KBio2_002564; DivK1c_006401; MEGxp0_000568; MolMap_000022; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; TNP00151; SPECTRUM210296; KBio2_003368; SPBio_000636; K00046; NCGC00025005-03; NCGC00015479-05; Sophoricol; Lopac0_000520; Spectrum2_000638; ZINC18825330; G 6649; NCGC00015479-02; 4,5,7-Trihydroxyiso-flavone; Genistein; 4',5,7-Trihydroxyisoflavone; MLS000738127; nchembio.2007.28-comp32; LS-1266; KBio3_003042; KBioSS_002573; Bonistein; NCGC00025005-02; NCGC00169711-02; nchembio.168-comp7; ACon1_001065; AC-472; AB1004490
CompanyDSM Nutritional Products
IndicationProstate CancerPhase II    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15
(11)19/h1-7,16-18H
InChIKeyTZBJGXHYKVUXJN-UHFFFAOYSA-N
Canonical SMILESC1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O    
CAS NumberCAS 446-72-0
PubChem Compound IDCID 5280961.
PubChem Substance IDSID 8792.
ChEBI28088;
ClinicalTrials.govNCT00546039;
TargetPeroxisome proliferator activated receptor gammaAgonist[2]
Ref 1New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. To Reference
Ref 2Effect of dietary genistein on Phase II and antioxidant enzymes in rat liver. Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):85-92. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543